News & Resources

Nextgen TCR therapies can improve diagnosis and treatment regimens

Jan 19, 2023

Our CEO and co-founder, Choon-Peng (Choon) Ng recently spoke with BioSpectrum Asia about how our unique Deep Immunomics and machine learning platforms can discover and...

$

ImmunoScape To Present at the 7th Annual CAR-TCR Summit

Sep 14, 2022

ImmunoScape To Present at the 7th Annual CAR-TCR Summit San Diego, California and Singapore – September 14, 2022 – ImmunoScape, a pre-clinical biotechnology company...

$

ImmunoScape Raises $14M to Facilitate the Discovery and Characterization of Cancer-Specific T-cell Receptors

Sep 14, 2022

ImmunoScape Raises $14M to Facilitate the Discovery and Characterization of Cancer-Specific T-cell Receptors Anzu Partners led the $14M financing round with...

$

Read our latest publication together with NAIAD and Johns Hopkins University on the T cell response to the mutations found in the omicron variant of SARS-CoV-2

Mar 21, 2022

ImmunoScape has continued its COVID-19 collaboration with NIAID and the Johns Hopkins University. Read our paper here: Minimal Crossover between Mutations Associated...

$

ImmunoScape Inks Licensing Deal with Pure MHC to Advance Development of Novel TCR- Based Therapies

Feb 16, 2022

SINGAPORE, SAN DIEGO, OKLAHOMA CITY, and AUSTIN – February 16, 2022 – ImmunoScape, a pre-clinical biotechnology company focused on the discovery and development of...

$

ImmunoScape Appoints Renowned Immuno-Oncology Expert Adrian Woolfson, BM BCh, PhD, to Board of Directors

Jul 28, 2021

SINGAPORE and SAN DIEGO – July 28, 2021 – ImmunoScape, a biotech company with an immunomics-based technology platform that provides novel insights into the human immune...

$